Drug intelligence / Profile preview

chloropyramine

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular, Topical, Ophthalmic
01

Overview

Chloropyramine is a first-generation antihistamine of the ethylenediamine class, primarily used in several Eastern European countries for the treatment of allergic conditions such as allergic conjunctivitis, allergic rhinitis, bronchial asthma, angioedema (Quincke's edema), urticaria, and other atopic reactions. It is also indicated for allergic reactions to insect bites, food and drug allergies, and anaphylactic shock. Chloropyramine acts as a competitive reversible antagonist (or inverse agonist) at the histamine H1 receptor. By blocking this receptor, it inhibits vasodilation, increased vascular permeability, and tissue edema associated with histamine release. The drug also exhibits anticholinergic properties due to its ability to cross the blood-brain barrier; these effects contribute to side effects such as drowsiness and dry mouth[1][2][3][5][6]. In addition to its antihistaminic action in allergy management, preclinical data suggest that chloropyramine can inhibit Vascular endothelial growth factor receptor 3 and Focal adhesion kinase activity in vitro and reduce tumor growth in vivo[7].

Brand names
Synopen
Other names
chloropyramine hydrochloride
02

Targets

VEGFR4 (Vascular endothelial growth factor Receptor-3)mAChR (Muscarinic acetylcholine receptors)FAK (Focal adhesion kinase)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on chloropyramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on chloropyramine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call